MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) Stock Price Today
Aura AI Summary
Key Stats
- $79.22BMarket Cap
- -Volume
- Consumer StaplesSector
- $64.9952W High
- $51.5152W Low
- -Typical Hold Time
- $99.56BEnterprise Value
- 3.35%Div Yield
- -Trading Activity
Track MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, MONDELEZ INTERNATIONAL INC Common Stock has traded between a low of $51.51 and a high of $64.99, highlighting its annual price range. Buy and sell MONDELEZ INTERNATIONAL INC Common Stock shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Most Recent News
Alumis stock plunges 57% after lupus drug trial fails, but psoriasis drug progress continues.
Alumis' stock dropped 56.58% after its Phase II lupus drug trial failed to meet main goals, causing a significant market reaction. However, positive results in a subgroup of lupus patients with a high interferon gene signature offer a potential path ...
SPACs, biotech, geothermal, and AI stocks rally with major deals and volatility driving gains
SPAC stocks like Rising Dragon Acquisition surged nearly 47% amid volatility, while biotech firm bioAffinity Technologies jumped 44% after a reverse stock split. Renewable energy company Fervo Energy gained 28% following a major geothermal power deal...
Alumis plunges 57% after trial failure; Enovis falls 16% on robotics acquisition news
Alumis Inc. shares dropped 56.76% after its Phase 2b trial for a lupus drug failed to meet key goals, though some patient groups showed promise. Enovis Corporation shares fell 16.51% following its announcement to acquire eCential Robotics for €155 mi...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.